What Will Happen to Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Next? The Stock Has Increase in Shorts

January 14, 2018 - By Vivian Park

 What Will Happen to Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Next? The Stock Has Increase in Shorts

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It is negative, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.
Geode Cap Mgmt Llc owns 38,315 shares for 0% of their portfolio. Next Fincl Grp Inc invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields Management Llc has 725,348 shares for 0.17% of their portfolio. Focused Wealth Mgmt owns 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 45 shares. California Pub Employees Retirement reported 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). 68 are owned by Wells Fargo And Com Mn. Wellington Shields Ltd Liability Corp invested 0.29% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Jpmorgan Chase has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Guggenheim Limited Liability accumulated 12,242 shares or 0% of the stock. Renaissance Limited Liability invested in 0% or 112,900 shares. Vanguard Inc stated it has 358,972 shares. Moors Cabot Inc reported 26,053 shares or 0.01% of all its holdings. Everett Harris Ca invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Morgan Stanley has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Raymond James Financial Services Advsrs Incorporated owns 55,135 shares.

The stock of Casi Pharmaceuticals Incorporated (NASDAQ:CASI) registered an increase of 19.72% in short interest. CASI’s total short interest was 745,400 shares in January as published by FINRA. Its up 19.72% from 622,600 shares, reported previously. With 458,200 shares average volume, it will take short sellers 2 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Incorporated’s float is 2.06%.

The stock decreased 0.79% or $0.03 during the last trading session, reaching $3.75. About 281,022 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since January 14, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $244.00 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, September 22 by Maxim Group. The stock has “Buy” rating by Maxim Group on Monday, August 14. H.C. Wainwright initiated CASI Pharmaceuticals, Inc. (NASDAQ:CASI) rating on Thursday, October 29. H.C. Wainwright has “Buy” rating and $3 target.

More news for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) were recently published by: Prnewswire.com, which released: “CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer” on May 18, 2017. Prnewswire.com‘s article titled: “CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study …” and published on April 14, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: